Amgen announced a $600 million investment to build a new state-of-the-art research and development facility in Thousand Oaks, California, slated to accelerate next-generation drug discovery and create hundreds of jobs. Additionally, Royalty Pharma secured up to $950 million for royalty interests in Amgen’s immunotherapy Imdelltra for extensive-stage small cell lung cancer, a product that has exceeded sales expectations in 2025. These strategic moves underscore Amgen’s continued expansion and commitments to innovation and commercialization in oncology and beyond.